A non-binding letter of intent has been executed by Shuttle Pharmaceuticals Holdings, Inc.,a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, to acquire Molecule.ai, a pioneering artificial intelligence company. a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, to acquire Molecule.ai, a pioneering artificial intelligence company.

Founded by Dr. ZT Zhang, Molecule.ai has developed a state-of-the-art platform that leverages advanced machine learning models, including large language models (LLMs), to fundamentally transform the drug discovery and development process. The platform is designed to provide industry-leading accuracy and efficiency by enabling researchers to shorten development timelines, reduce costs, and increase the probability of identifying successful therapeutic candidates.

Key capabilities of the Molecule.ai platform include Molecule Property Prediction and Reasoning for large-scale evaluation of compound libraries, advanced Drug-Target Interaction Modeling to enable precise therapeutic design, and an Agentic AI Mode, which is an autonomous framework capable of performing multi-step drug discovery workflows from screening through optimization, significantly reducing manual effort.

The terms of the acquisition outline that Shuttle Pharma will acquire all rights and assume all liabilities of Molecule.ai. The deal, which will also see Molecule.ai extend its platform to fully support Drug-Target Interaction and add the first version of the Agentic AI mode, involves a purchase price of $10 million, payable in a combination of cash and common shares of Shuttle, subject to the completion of certain determined milestones. This acquisition positions Shuttle Pharma to integrate cutting-edge AI into its mission of developing radiation sensitizers to increase cancer cure rates and improve patient outcomes.